BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $GALD.SW readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07074977-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~CPUO readout (P2) · Galderma R&D $GALD.SW
DESCRIPTION:Proof of Concept Study to Assess the Pharmacokinetics/Pharmacod
 ynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (
 CPUO)\n\nPrimary completion date: 2026-12 (estimated) — month only\, sho
 wn on the 1st\nOriginally planned: 2026-09 (+3.0 months)\nPhase 2 · Other
  · Chronic Pruritus of Unknown Origin\nEnrollment: 50 · Sites: 26\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/ra
 dar.html?nct=NCT07074977\nhttps://clinicaltrials.gov/study/NCT07074977
URL:https://datacutoff.com/radar.html?nct=NCT07074977
CATEGORIES:Other,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07186413-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AKLIEF readout (P3) · Galderma R&D $GALD.SW
DESCRIPTION:A Study to Compare the Efficacy\, Safety and Pharmacokinetics o
 f Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris\n\nPri
 mary completion date: 2026-12-31 (estimated)\nPhase 3 · Immuno · Acne Vu
 lgaris\nEnrollment: 561 · Sites: 1\n\nPrimary completion = last participa
 nt's primary-endpoint data collected\; topline results usually follow week
 s to months later. Sponsor-reported\, often an estimate. Not investment ad
 vice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07186413\nhttps:
 //clinicaltrials.gov/study/NCT07186413
URL:https://datacutoff.com/radar.html?nct=NCT07186413
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762833-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Nemolizumab 30 mg readout (P3) · Galderma R&D $GALD.SW
DESCRIPTION:Randomized\, Double-blind\, Placebo-controlled Study of Nemoliz
 umab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis\n\nPrim
 ary completion date: 2027-10-28 (estimated)\nPhase 3 · Immuno · Atopic D
 ermatitis\nEnrollment: 240 · Sites: 1\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07762833\nhtt
 ps://clinicaltrials.gov/study/NCT07762833
URL:https://datacutoff.com/radar.html?nct=NCT07762833
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
